Know Cancer

forgot password

Phase II Study of the Anti-Vascular Endothelial Growth Factor (α-VEGF) Monoclonal Antibody Bevacizumab in Combination With Fixed Dose Rate (FDR) Gemcitabine and Rapid-Fractionation Radiotherapy in the Pre-operative Treatment of Potentially- Resectable Pancreatic Adenocarcinoma

Phase 2
18 Years
80 Years
Open (Enrolling)
Pancreatic Cancer

Thank you

Trial Information

Phase II Study of the Anti-Vascular Endothelial Growth Factor (α-VEGF) Monoclonal Antibody Bevacizumab in Combination With Fixed Dose Rate (FDR) Gemcitabine and Rapid-Fractionation Radiotherapy in the Pre-operative Treatment of Potentially- Resectable Pancreatic Adenocarcinoma

This is a 2 stage phase II study of bevacizumab (10 mg/kg) and fixed dose rate (FDR)
gemcitabine (1500 mg/m2 at 10 mg/kg/min) in combination with sequential rapid fractionation
radiotherapy (30 Gy total) in the preoperative treatment of potentially-resectable subjects
with adenocarcinoma of the pancreas. The purpose of this study is to determine the rate of
margin negative surgical resection (R0 resection rate) and the rate of complete pathological
response in patients with resected pancreas cancer. The overall goal of this study is to
determine the merit of this novel regimen for further study in a Phase III trial examining
time to progression and overall survival. Based on the need for 48 evaluable subjects to
evaluate the primary endpoints, the study will be opened with a target accrual of 60
subjects given an expected 20% rate of attrition observed in prior studies of subjects with
pancreas cancer at UPCI.

Inclusion Criteria:

- Histologic or cytologic proof of pancreatic adenocarcinoma.

- Subjects with biopsy-proven adenocarcinoma of the pancreas which is potentially
resectable by preoperative imaging. Subjects will be considered potentially
resectable using criteria defined by Pisters (Pisters et al., 2001):

- if imaging detects no evidence of extrapancreatic disease;

- no evidence of tumor extension to the superior mesenteric artery (SMA) or celiac axis
(intact fat plane between the tumor and the adjacent visceral artery),

- patent superior mesenteric-portal vein confluence

- no encasement of portal or superior mesenteric vein.

- Karnofsky performance status ≥ 80.

- No active second malignancy except for basal cell carcinoma of the skin

- Normal renal, hepatic, and hematologic function at the time of enrollment as
evidenced by:

- Serum creatinine level ≤1.6 mg/dl ( Calculated Creat clearance >50)

- Serum total bilirubin level ≤1.5 X ULN

- Urine protein excretion ≤ 1+ by urine dipstick

- White blood cell count ≥ 3.5x109/ml per ml and platelet count ≥ 100x109 per ml

- Age >18 years.

- Children are excluded because of toxic effects of bevacizumab and gemcitabine on
growth and development during preclinical studies.

- For subjects with obstructive jaundice, the biliary tract must be drained with a
temporary plastic or a short permanent metallic biliary stent.

- Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria:

- Disease-Specific Exclusions

- Subjects who have received chemotherapy within 12 months prior to study entry.

- Prior use of radiotherapy or investigational agents for pancreatic cancer.

- Subjects who have undergone laparotomy for pancreas cancer within 6 weeks

- Any evidence of metastasis to distant organs (liver, lung, peritoneum).

- Symptomatic or endoscopic evidence of gastric outlet obstruction

• Endoscopic findings suggesting tumor erosion into the gastrointestinal mucosa.

- Concurrent malignancies with evidence of active or measurable disease except basal
cell carcinoma of the skin.

- General Medical Exclusions

- Inability to adhere to study and/or follow-up procedures

- History of allergic reactions or hypersensitivity to the study drugs (bevacizumab,
gemcitabine, and proton pump inhibitors).

- Other concurrent experimental therapy.

- Because subjects with immune deficiency are at increased risk for lethal infections
when treated with marrow-suppressive therapy, HIV-positive subjects receiving
combination anti-retroviral therapy are excluded from the study.

- Bevacizumab-Specific Exclusions

- Subjects who have had recent surgery (prior 6 weeks)

- Core biopsy or other minor surgical procedure, excluding placement of a vascular
access device, within 7 days prior to study enrollment

- Subjects with the following co-morbid medical conditions:

- History of myocardial infarction or unstable angina within 12 months prior to study

- Ascites

- Pregnancy/lactation - The effects of the study drugs on the developing human fetus
are unknown. For this reason and because bevacizumab, gemcitabine, and radiation
therapy used in this trial are known to be teratogenic in animal studies, women and
men of child-bearing potential must agree to use adequate contraception (hormonal or
barrier method of birth control; abstinence) from the time of study entry until 6
months after the completion of study participation. Should a woman become pregnant or
suspect she is pregnant while participating in this study, she should inform her
treating physician immediately. A serum pregnancy test for those females of
childbearing potential must be done prior to their receiving study drugs. Due to the
combined effects of chemotherapy and radiation, breastfeeding is not allowed for 6
months after the completion of study participation.

- Regular aspirin use > 325 mg per day

- Regular NSAID use

- Bleeding diathesis, coagulopathy, need for full-dose anticoagulation or INR > 1.5

- Known central nervous system metastasis

- Previous cerebrovascular accident, transient ischemic attack, or seizure (within 6

- Serious non-healing wound, ulcer, or bone fracture

- History of abdominal fistula, gastrointestinal perforation, diverticulitis, or
intra-abdominal abscess within 6 months prior to study enrollment.

- Recent hemoptysis,

- Uncontrolled hypertension (defined as systolic blood pressure >150 and/or diastolic
blood pressure > 100 mmHg on antihypertensive medications)

- Any prior history of hypertensive crisis or hypertensive encephalopathy

- New York Heart Association (NYHA) grade 2 or greater congestive heart failure (see
Appendix I)

- Prior deep venous thrombosis or pulmonary embolism

- Urine protein excretion 2+ or ≥ 1 g per 24 hours

- Peripheral vascular disease such as lower extremity claudication and rest pain or
prior lower extremity vascular surgery for arterial insufficiency

- Dyspnea requiring supplemental oxygen

Type of Study:


Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the rate of margin negative surgical resection (R0 resection rate), and to establish the rate of complete pathologic response in resected pancreas cancer after neoadjuvant treatment.

Outcome Time Frame:

6 months

Safety Issue:


Principal Investigator

Herbert J. Zeh, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Pittsburgh


United States: Institutional Review Board

Study ID:




Start Date:

December 2006

Completion Date:

December 2012

Related Keywords:

  • Pancreatic Cancer
  • pancreas
  • pancreatic
  • cancer
  • resectable
  • Pancreatic Neoplasms



University of Pittsburgh Medical Centers Pittsburgh, Pennsylvania  15213